Harmony Biosciences Holdings, Inc.
Moat Score — Harmony Biosciences Holdings, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | WAKIX's regulatory status as the only FDA-approved, DEA-non-scheduled narcolepsy treatment, combined with Harmony's exclusive licenses from Bioprojet on pitolisant and next-generation formulations, constitutes real, legally-protected differentiation. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Harmony pays Bioprojet royalties of 13%-24% on WAKIX net sales and relies on single-source API suppliers, giving it no structural cost advantage over larger pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | WAKIX is priced above generic stimulants and below sodium oxybate products, reflecting a differentiated value position in a category where physicians value its non-scheduled status, though Harmony has not run head-to-head trials to justify that premium directly. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products like WAKIX have no network effect; one patient's use of the drug does not make it more valuable to another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Patients stabilized on WAKIX face some switching friction given titration requirements and physician familiarity, but this is a moderate rather than high barrier given legitimate alternative sleep/wake therapies exist. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Harmony's commercial infrastructure is built around WAKIX within a single, well-defined narcolepsy market (~$2.9 billion U.S. net sales value), giving it focus, but its near-total dependence on one product limits the efficient-scale benefits a broader portfolio would provide. |